Comments

Response to “Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients”

Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padova
Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padova
Haematologica Early view Nov 18, 2021 https://doi.org/10.3324/haematol.2021.280199